Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Other Operating Expenses: 2012-2025

Historic Other Operating Expenses for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $25.1 million.

  • Veracyte's Other Operating Expenses rose 5.91% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.0 million, marking a year-over-year decrease of 5.00%. This contributed to the annual value of $102.1 million for FY2024, which is 40.62% down from last year.
  • According to the latest figures from Q3 2025, Veracyte's Other Operating Expenses is $25.1 million, which was down 46.00% from $46.4 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's Other Operating Expenses ranged from a high of $59.8 million in Q3 2023 and a low of -$64.6 million during Q4 2022.
  • In the last 3 years, Veracyte's Other Operating Expenses had a median value of $26.3 million in 2023 and averaged $36.5 million.
  • In the last 5 years, Veracyte's Other Operating Expenses plummeted by 227.81% in 2022 and then soared by 189.47% in 2023.
  • Veracyte's Other Operating Expenses (Quarterly) stood at $50.6 million in 2021, then tumbled by 227.81% to -$64.6 million in 2022, then spiked by 189.47% to $57.8 million in 2023, then crashed by 50.93% to $28.4 million in 2024, then climbed by 5.91% to $25.1 million in 2025.
  • Its Other Operating Expenses stands at $25.1 million for Q3 2025, versus $46.4 million for Q2 2025 and $25.1 million for Q1 2025.